2023-09-10 17:34:12
RSV (respiratory syncytial virus), the cause of bronchiolitis, already has three vaccines approved in recent weeks in Europe and the United States. asiraj – stock.adobe.com
The market for treatment once morest RSV (respiratory syncytial virus), the cause of bronchiolitis, might ultimately reach $10 to $12 billion per year.
Three years following Covid, this is the new playground of Big Pharma. RSV (respiratory syncytial virus), the cause of bronchiolitis, already has three vaccines approved in recent weeks in Europe and the United States. Deliveries have started in some countries.
Last year, the triple epidemic of influenza-bronchiolitis-Covid brought health systems to their knees, barely recovering from two years of health crisis. Bronchiolitis, which particularly affects babies and the elderly, had been particularly severe. “It is rare to see a new market open up in the pharmaceutical industry, notes Vincent Meunier, sector specialist at Bryan, Garnier & Co. Against RSV, we went from a situation of nothingness to a battle between giants.»
Read alsoFinally protection once morest bronchiolitis in infants
Only one treatment once morest severe forms existed until then, AstraZeneca’s Synagis. Six decades of research had ended in failure. Worldwide, RSV is the cause each year…
This article is reserved for subscribers. You have 78% left to discover.
Do you want to read more?
Unlock all items immediately.
Already subscribed? Log in
1694393562
#battle #pharmaceutical #giants
